MMSET is the key molecular target in t(4;14) myeloma

por Mirabella, F, Wu, P, Wardell, C P, Kaiser, M F, Walker, B A, Johnson, D C, Morgan, G J
Publicado 2013

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients

por Walker, B A, Wardell, C P, Brioli, A, Boyle, E, Kaiser, M F, Begum, D B, Dahir, N B, Johnson, D C, Ross, F M, Davies, F E, Morgan, G J
Publicado 2014

Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs

por Jones, J. R., Barber, A., Le Bihan, Y-V, Weinhold, N., Ashby, C., Walker, B. A., Wardell, C. P., Wang, H., Kaiser, M. F., Jackson, G. H., Davies, F. E., Chopra, R., Morgan, G. J., Pawlyn, C.
Publicado 2021

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

por Rasche, L, Alapat, D, Kumar, M, Gershner, G, McDonald, J, Wardell, C.P, Samant, R, Van Hemert, R, Epstein, J, Williams, A.F, Thanendrarajan, S, Schinke, C, Bauer, M, Ashby, C, Tytarenko, R.G, van Rhee, F, Walker, B.A, Zangari, M, Barlogie, B, Davies, F.E, Morgan, G.J, Weinhold, N
Publicado 2018